Shaf Keshavjee
Thoracic surgeon and Director of the Toronto Lung Transplant Program who led development of the Toronto ex vivo lung perfusion system.
As of . Primary source: UHN Research profile.
Summary
According to his UHN Research profile, Shaf Keshavjee is Surgeon-in-Chief of Sprott Surgery at University Health Network, Director of the Toronto Lung Transplant Program and Director of the Latner Thoracic Research Laboratories, and a Professor in the Department of Surgery at the University of Toronto. His laboratory focuses on molecular mechanisms of lung preservation, injury and repair, and he led development of the Toronto ex vivo lung perfusion (EVLP) system. The profile does not describe CLAD research specifically.
Ranking method and caveats
Methodology for the researcher ranking
- Query: OpenAlex works of type article or review whose title or abstract contains "chronic lung allograft dysfunction" or "restrictive allograft syndrome", or "bronchiolitis obliterans" together with lung transplant terms. Retracted works and meeting-abstract supplements are removed.
- Window and date: works published 2016-10-11 to 2026-10-10; counts retrieved 2026-10-10 (2,461 works, 8,698 author profiles after merging).
- Counting: the rank is by total citations of the author's papers (whole counting). Fractional counts, first or last author papers and counts without the two 2019 ISHLT consensus papers are shown on each record.
- Identity: authors are identified by OpenAlex author identifier and ORCID. Duplicate profiles were merged by identical ORCID, or by compatible name plus shared institution. Only the top 30 entries were checked by hand.
- Rising researchers: a separate numbered list ordered by citations in the 5 years from 2021-10-11, for authors whose first paper in the corpus is dated 2019 or later and who have at least 5 papers in that window. It is a proxy, not a measure of career stage.
- Caveats: the corpus includes papers only partly about CLAD; consensus papers inflate some totals; recent papers are under-cited; author identifiers can be wrong; citations measure attention, not quality or clinical skill.
Details
- role
- Surgeon-in-Chief, Sprott Surgery; Director, Toronto Lung Transplant Program; Professor (University of Toronto)
- affiliation
- Toronto Lung Transplant Program, University Health Network; University of Toronto
- citation rank 10y
- 14 of 8,698 author profiles (top 100 listed)
- papers 10y
- 126
- fractional papers 10y
- 11.44
- citations 10y
- 1320
- fractional citations 10y
- 102.5
- lead author papers 10y
- 9
- citations excluding two ishlt2019consensus papers
- 1320
- rank excluding two ishlt2019consensus papers
- 7
- ranking retrieved
- 2026-10-10
- orcid
- 0000-0003-4547-8094
- openalex author id
- A5086297813
- merged open alex profiles
- 2
- affiliation basis
- ORCID record, employment entries without an end date (self-asserted, may be out of date)
Sources and links
- UHN Research profile (primary)
- OpenAlex author profile (ranking source)
- ORCID record
- Most-cited CLAD paper in corpus: Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system (The Journal of Heart and Lung Transplantation, 2020); 77 citations; DOI 10.1016/j.healun.2020.04.012
- Most-cited CLAD paper in corpus: A B cell–dependent pathway drives chronic lung allograft rejection after ischemia–reperfusion injury in mice (American Journal of Transplantation, 2019); 56 citations; DOI 10.1111/ajt.15550
- Most-cited CLAD paper in corpus: The impact of first untreated subclinical minimal acute rejection on risk for chronic lung allograft dysfunction or death after lung transplantation (American Journal of Transplantation, 2020); 51 citations; DOI 10.1111/ajt.15561
- Most-cited CLAD paper in corpus: Transcripts associated with chronic lung allograft dysfunction in transbronchial biopsies of lung transplants (American Journal of Transplantation, 2022); 32 citations; DOI 10.1111/ajt.16895
- Most-cited CLAD paper in corpus: Eosinophils in transbronchial biopsies: a predictor of chronic lung allograft dysfunction and reduced survival after lung transplantation — a retrospective single‐center cohort study (Transplant International, 2021); 24 citations; DOI 10.1111/tri.13760
Related
Links from this record
- member of: Toronto Lung Transplant Program (University Health Network)
- author: Center variability in the prognostic value of a cumulative acute cellular rejection "A-score" for long-term lung transplant outcomes
- author: Eosinophils in transbronchial biopsies: a predictor of chronic lung allograft dysfunction and reduced survival after lung transplantation — a retrospective single‐center cohort study.
- author: Long-term Outcomes of Lung Transplant With Ex Vivo Lung Perfusion
- author: Quantitative chest CT for subtyping chronic lung allograft dysfunction and its association with survival.
- author: Distinct fibrotic, epithelial and immune transcriptomic programs in phenotypes of chronic lung allograft dysfunction
- author: The impact of first untreated subclinical minimal acute rejection on risk for chronic lung allograft dysfunction or death after lung transplantation.
- author: Pulmonary epithelial markers in phenotypes of chronic lung allograft dysfunction
- author: Bronchoalveolar lavage cytokine-based risk stratification of clinically-stable lung transplant recipients with undefined rejection: Further insights from a follow-up investigation
- author: Local intragraft humoral immune responses in chronic lung allograft dysfunction.
- author: Emergence of a senescent and inflammatory pulmonary CD4+ T cell population prior to lung allograft failure
- author: Triaging donor lungs based on a microaspiration signature that predicts adverse recipient outcome
- author: Oesophageal stasis is a risk factor for chronic lung allograft dysfunction and allograft failure in lung transplant recipients.
- author: Airway pepsinogen A4 identifies lung transplant recipients with microaspiration and predicts chronic lung allograft dysfunction
- author: Spectrum of chronic lung allograft dysfunction pathology in human lung transplantation.
- author: Donor and recipient human leukocyte antigen-G polymorphisms modulate the risk of adverse immunologic events following lung transplantation
- author: Intra-subject variability in oscillometry correlates with acute rejection and CLAD post-lung transplant
- author: Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system
- author: Transcripts associated with chronic lung allograft dysfunction in transbronchial biopsies of lung transplants
Linked from (derived)
- coauthor: Center variability in the prognostic value of a cumulative acute cellular rejection "A-score" for long-term lung transplant outcomes
- coauthor: Pulmonary epithelial markers in phenotypes of chronic lung allograft dysfunction
- coauthor: Bronchoalveolar lavage cytokine-based risk stratification of clinically-stable lung transplant recipients with undefined rejection: Further insights from a follow-up investigation
- coauthor: Emergence of a senescent and inflammatory pulmonary CD4+ T cell population prior to lung allograft failure
- coauthor: Triaging donor lungs based on a microaspiration signature that predicts adverse recipient outcome
- coauthor: Airway pepsinogen A4 identifies lung transplant recipients with microaspiration and predicts chronic lung allograft dysfunction
- coauthor: Donor and recipient human leukocyte antigen-G polymorphisms modulate the risk of adverse immunologic events following lung transplantation
- coauthor: Intra-subject variability in oscillometry correlates with acute rejection and CLAD post-lung transplant
Known gaps in this record
- current funding
- ORCID identifier
- specific CLAD research focus
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.